NORTHWEST BIOTHERAPEUTICS INC (NWBO)

Pharmaceutical Preparations · market cap $273M · as of 2026-07-08

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Northwest Biotherapeutics (NWBO) is a development-stage Maryland-based immunotherapy company with 25 employees and a $411M market cap at ~$0.25/share. Its lead asset is Shenwu Capsule in Phase 3 for Mild Cognitive Impairment — a notable pivot from its historical oncology focus — alongside a Phase 2 lithium carbonate program in Major Depressive Disorder. No near-term catalysts are publicly calendared.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Shenwu Capsule	Phase 3	Mild Cognitive Impairment
Lithium Carbonate	Phase 2	Major Depressive Disorder

Price & technical context

3-month

-16.7%

6-month

-27.4%

12-month

-40.5%

52-wk range

$0.15–$0.32

vs 50-day MA

-11.9%

vs 200-day MA

-29.0%

Realized vol

66.2%

Max drawdown

-65.7%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for NWBO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.